Pacific Vision Foundation

Summary

What do they do? Pacific Vision Foundation supports charitable eye care, education and research in San Francisco. Its patient access routes include the Lions Eye Clinic and referrals for uninsured or low-income patients. The Foundation reports 2,542 surgeries and 570 charity cases cumulatively since 2020, but these mixed counts do not identify annual unique first-eye cataract patients. More

Why this approach interests us

Access to cataract surgery can restore useful vision for uninsured people who would otherwise wait for care.
The Foundation connects charitable support with eye-care providers and a means-tested patient referral route.
A randomized first-eye surgery trial provides a clinical starting point, rather than relying only on surgical charges or testimonials.

Our main reservations

Current public figures do not establish how many additional first-eye patients an unrestricted donation would enable.
The trial involved older women outside the local program; local waiting times, severity and alternative care are uncertain.
Actual household payments, lost pay and recipient residence are planning assumptions, and the other organizational activities remain unquantified.

What do you get for your dollar?

Our conditional estimate is $1.4M per DALY in the Bay Area and $30.5M for San Francisco recipients. An illustrative $10,000 comparison models 0.50 additional first-eye courses offered and approximately 0.45 completed courses, not a purchasable donation offer. The modeled clinical benefit is positive, while net household-resource effects are slightly negative centrally.

bay area: $1.4M — Per ten combined health and household-resource equivalents.
san francisco: $30.5M — Separate residence prior, nested within the Bay estimate.
health only — bay: $13.4M — Signed household costs make the combined estimate slightly less favorable.

1. What do they do?

Pacific Vision Foundation supports charitable eye care, education and research in San Francisco. Its patient access routes include the Lions Eye Clinic and referrals for uninsured or low-income patients. The Foundation reports 2,542 surgeries and 570 charity cases cumulatively since 2020, but these mixed counts do not identify annual unique first-eye cataract patients.

Allocate the ordinary gift

10% first-eye support;10% other clinical,15% education/research,40% building/capital and25% central/other support. These are explicit priors, not audited shares.

Support unique assigned courses

$10,000 at$1,000/course funds10 nominal first-eye courses;50% financing additionality yields5 added courses. Failed referrals stay within course costing.

Transfer the finite trial contrast

0.056 integrated one-year trial QALY ×50% local clinical/comparator fit; no second eye, extra duration, success multiplier or lifetime blindness avoidance.

Retain partners and regional scope

One shared outcome, outside clinical inputs, real later-care baseline and nested patient-residence priors. SF clinical location alone is insufficient.

Scope of this review. The complete donation remains the numerator. The modeled cataract pathway is only one organizational activity; other portfolio benefits and comprehensive economic costs remain unquantified.

2. Monitoring and information sharing

Mixed clinical access, training and facilities portfolio

Current primary program descriptions and2025 impact report. 2,542 surgeries in2025;570 charity cases cumulative since2020, not all annual first-eye cases.

Our assessment. No division of mixed/cumulative output into annual foundation cost; annual charity first-eye count and residence unknown.

First-eye expedited surgery versus roughly one-year wait

Randomized-assignment economic analysis among288 of306 older women. 0.056 integrated QALY difference;18 missing six-month EQ-5D outcomes excluded.

Our assessment. Utility shape was assumed for the year; no automatic attrition/success multiplier or extra falls effect. Local transfer remains a judgment.

PVF, disregarded property entity and controlled surgery-center interest

Primary990 and related-entity schedule. Internal charity transfer and separate rental netting expose broader financial scope.

Our assessment. Standalone filing is not consolidated clinical revenue, whole resource consumption or marginal allocation.

3. Qualitative assessment

Access to cataract surgery can restore useful vision for uninsured people who would otherwise wait for care.

Key reservations

Current public figures do not establish how many additional first-eye patients an unrestricted donation would enable.
The trial involved older women outside the local program; local waiting times, severity and alternative care are uncertain.
Actual household payments, lost pay and recipient residence are planning assumptions, and the other organizational activities remain unquantified.

Benefits not included in our estimate

Other cataract/second-eye, retina, corneal and glaucoma care
Low-vision rehabilitation and other clinical support
Residency, fellowship, research and professional education
Future facilities and surgery-center sustainability benefits
Fall-related gains already included in trial utility; no separate addition
Health beyond the one-year earlier-care contrast
Unmeasured other portfolio effects, earnings of additional survivors and comprehensive external economic costs.

4. What do you get for your dollar?

Earlier first-eye care, not the retail value of surgery, is the modeled benefit.

GiveBetter sees plausible value in helping patients obtain sight-restoring care sooner. We estimate $1.4M per DALY for Bay Area recipients under the current conditional assumptions. The $10,000 comparison assigns 10% to this pathway and assumes 50% of the resulting support enables additional courses, at $1,000 per offered course: 0.50 unique first-eye courses offered and about 0.45 completed. We exclude the clinical benefit of patients who would purchase equivalent care or obtain it free, leaving 80% initially unmet. The clinical anchor is a 0.056 integrated first-year QALY difference in an expedited-versus-waiting trial; judged population and timing transfers reduce that contrast, rather than repeating it every year. Vision can matter for daily functioning and paid work, but local net earnings have not been measured. Actual otherwise-paid bills, travel, medicine and lost disposable pay are modeled separately; waived charges and lifetime wages of additional survivors are not household gains.

DALY is our one-year comparison unit. QALY-based health gains and income-welfare equivalents retain their original assumptions; they are not measured clinical DALYs. These are uncertain estimates, not measured returns or verified donation offers.

How we calculate the estimate

Current conditional estimate: donor dollars ÷ (local health years + signed local household-resource equivalents)
Per $10,000: US health 0.0082966 + resources -0.0001071 = 0.0081895. Bay $13.6M; SF $3.1M.

Model inputs and assumptions

Additional first-eye course support: 10% allocation; 50% financing response; $1,000/course (range: $250–$3,500 course support; 0%–75% response). The monthly $250 surgery appeal does not establish a one-time complete course, unrestricted allocation or marginal slots. Cap10 and the software gift domain are comparison assumptions, not verified capacity. Judgment.
First-year clinical gain: 0.056 × 75% population transfer × 50% timing transfer (range: 0.006 or adverse trial contrast; full-year timing). The trial compared expedited first-eye surgery with routine waiting in 306 women over 70. Its integrated first-year contrast is not an annuity or local causal measurement. Trial plus transfer judgments.
Completion and alternative care: 90% completion; 5% purchased, 15% free, 80% unmet (range: Half/zero completion; all-purchased/free alternatives). The .90 local benchmark assumes trial-comparable assignment completion, not a measured RCT rate. Relative completion adjusts departures from that benchmark without another central .90 attrition multiplier. Judgment.
Actual household resources: $30,000 baseline; $1,000 otherwise-paid bill; $25 travel; $20 medicine (range: Zero purchase saving; higher travel; net medicine savings). Actual household payments only, not insurer bills or retail surgical value. Buyer savings retain full welfare because matching clinical benefits cancel; every negative burden retains full weight. Judgment.
Net disposable paid work: 25% workers; one $100 lost paid day; zero central recovery pay (range: ±$500/year recovery; fractional recovery duration). The elderly external trial does not identify local earnings. Zero central recovery is an unidentified-sign planning case, not proof of no effect. Worker incidence is applied before logarithmic welfare conversion. Judgment.
Recipient residence and timing: Bay 90%; SF 40%; onset 0.25 years (range: Unknown/no local incidence; timing stresses). Surgery location does not establish residence. Onset survival and finite common-alive resource exposure are separate from the integrated clinical contrast. Judgment.

Assumption tests, not confidence limits

central: $1.4M Bay. Change the named assumption only; inspect the calculator for separate clinical and signed household components.
lowFunding: $2.7M Bay. Change the named assumption only; inspect the calculator for separate clinical and signed household components.
cash250Unverified: $339K Bay. Change the named assumption only; inspect the calculator for separate clinical and signed household components.
fullCostSupport: $4.7M Bay. Change the named assumption only; inspect the calculator for separate clinical and signed household components.
trialLower: $14.2M Bay. Change the named assumption only; inspect the calculator for separate clinical and signed household components.
payPositive: $1.3M Bay. Change the named assumption only; inspect the calculator for separate clinical and signed household components.
payNegative: $1.5M Bay. Change the named assumption only; inspect the calculator for separate clinical and signed household components.
unknownPayZeroPlaceholder: No finite positive price Bay. Change the named assumption only; inspect the calculator for separate clinical and signed household components.

Uncertainty. An unweighted conditional planning scenario, not an identified expected return or complete portfolio estimate. Current clinical and household benefits are reconstructed independently of the historical total.

Health and income effects

Household resources use the Coefficient Giving welfare crosswalk: 0.5 times the logarithmic annual disposable-resource change, multiplied by the affected population and discounted exposure. These are income-welfare equivalents, not measured clinical QALYs.

Buyer/free/unmet and worker/nonworker cohorts are separated before nonlinear conversion. Purchase savings, travel, medicine, lost pay and recovery pay update the same household baseline sequentially. Positive medicine/recovery welfare retains50% for possible overlap; every negative burden retains full weight.

Recovery pay has a finite common-alive horizon and no baseline earnings of additional survivors. A zero recovery duration does not erase actual lost-pay costs. Failed assignments retain acquisition expenses and independent harms; zero completed operations do not receive surgical health or pay benefits.

Unknown reach covers allocation, financing, course support and capacity; unknown clinical evidence covers the trial and transfer assumptions. Unavailable zero placeholders cannot prove absence. Known zero gift, no unmet recipients or no completion can establish appropriate absent routes, without erasing other costs.

Historical estimate — retained for comparison

The previous ordinary-gift clinical center was $794K Bay/$1.8M SF per DALY. The new conditional estimate is $1.4M Bay/$3.1M SF: explicit purchased/free alternatives, population and waiting-time transfers, onset timing and signed household costs replace the opaque inherited joint transfer. This is a change in assumptions and coverage, not measured deterioration. All 18 original full scenario outputs remain unchanged; the earlier selected-case $714,286 illustration is a different allocation boundary.

Whole gift, finite first-eye assignment effect: Nominal courses = gift × first-eye allocation / direct cash per course. Added courses = nominal × financing additionality. Benefit = added × integrated first-year trial QALY × local clinical/timing transfer. Subtract added-course extra harm and independent gift-date losses. Regional Q = benefit × benefit share − losses × loss share. All price numerators retain the entire gift.
US0.14 /Bay0.126 /SF0.056 QALYs. SF donor/gross/net prices $1.8M /$2.2M /$1.8M per DALY.

QALY conversion assumptions

Whole unrestricted gift: $100,000 (range: Domain $1–$1 billion). Entire ordinary gift retained; no priced restricted offer. Specified gift.
Direct first-eye course allocation: 10% (range: 5–40%; zero). Marginal portfolio prior, not historical charity-care expense ratio. Other90% cost retained. Explicit uncalibrated prior.
Direct cash per assigned unique first-eye course: $1,000 (range: $500–$2,000; $250 unverified sensitivity). Legacy constructed cash budget includes referral/noncompletion costs. Separate portfolio allocation retains central costs; no second-eye benefit. Explicit uncalibrated prior.
Integrated first-year trial QALY effect: 0.06 (range: 0.01 external lower-coordinate stress). Economic randomized-assignment analysis among288/306 with six-month utility extrapolation; not a local observed effect or full-cohort outcome. External integrated economic-trial result; transfer uncertain.
Local clinical/comparator transfer: 50% (range: 12.5–100%; zero; −50% harm). Joint population, severity, actual waiting-time and pathway-fit prior. No permanent-denial or lifetime extension. Explicit uncalibrated prior.
Funding additionality: 50% (range: 25–75%; zero). Added support versus existing PVF/Lions/CPMC/clinical financing; distinct from clinical transfer. Explicit uncalibrated prior.
Extra shared harm per added course: 0.00 gift-date PV QALY (range: 0.04 stress). Outside complications already incorporated in trial. Costs of failed referrals remain. Explicit uncalibrated prior.
Independent donor harm: 0.00 gift-date PV QALY (range: 0.20 at zero activity). Independent of additional surgery; no second discount. Explicit uncalibrated prior.
Other displaced care health: 0.00 gift-date PV QALY (range: 1.00 at target failure). Distinct lost alternative clinic/resource use; not canceled by zero cataract effect. Explicit uncalibrated prior.
Outside public resources: $0 (range: $500 stress). Narrow uninsured route, not proof of zero public resources throughout organization/partners. Real inputs only, no transfer sum. Explicit uncalibrated prior.
Outside private/partner resources: $2,500 (range: $2,000–$4,000; zero donor-pays case). Clinical/facility/lens inputs beyond direct cash and internal charity transfer. Unpriced prior, not charges. Explicit uncalibrated prior.
Otherwise later outside-care resources: $2,500 (range: $0–$4,000 scenarios). Unpriced offset conditional on later surgery, not permanent denial. No offset to retained whole-gift cash. Explicit uncalibrated prior.
Timing of counterfactual outside cost: 1 year (range: 0.25 short-wait sensitivity). Cost valuation parameter; health remains the already integrated one-year trial transfer. Shorter clinical wait requires separate clinical transfer judgment. Explicit uncalibrated prior.
Continuous resource discount: 3% (range: Domain 0–20%). No extra within-year health discount applied to integrated trial result. Explicit uncalibrated prior.
Other net real resource savings: $0 gift-date dollars (range: $150,000 diagnostic; signed domain). Separate resource savings, not patient welfare or transfers; negative denotes additional cost. Explicit uncalibrated prior.
Bay share of benefit: 90% (range: 70–95%). Unmeasured future residence share, not geography inferred from SF clinic location. Explicit uncalibrated prior.
SF share of benefit: 40% (range: 20–60%; zero). Independent nested residence prior; wider California/Nevada pathway retained. Explicit uncalibrated prior.
Bay share of losses: 90% (range: Nested domain 0–100%). Separate allocation of shared/independent/displaced-alternative harm. Explicit uncalibrated prior.
SF share of losses: 40% (range: Nested domain 0–100%). Can differ from health share; regions never summed. Explicit uncalibrated prior.

central: SF donor $1.8M per DALY. US/Bay/SF QALYs 0.14 / 0.126 / 0.056. Donor US/Bay/SF $7,142,857 / $7,936,508 / $17,857,143. Gross resources $125,000; gross US/Bay/SF prices $8,928,571 / $9,920,635 / $22,321,429. Net resources $100,369; net US/Bay/SF prices $7,169,245 / $7,965,828 / $17,923,113. Prices per DALY; signed net-resource diagnostics retained.
favorable_joint: SF donor $50K per DALY. US/Bay/SF QALYs 3.36 / 3.192 / 2.016. Donor US/Bay/SF $297,619 / $313,283 / $496,032. Gross resources $260,000; gross US/Bay/SF prices $773,810 / $814,536 / $1,289,683. Net resources $103,547; net US/Bay/SF prices $308,174 / $324,394 / $513,624. Prices per DALY; signed net-resource diagnostics retained.
pessimistic_positive: SF donor $266.7M per DALY. US/Bay/SF QALYs 0.001875 / 0.0013125 / 0.000375. Donor US/Bay/SF $533,333,333 / $761,904,762 / $2,666,666,667. Gross resources $110,000; gross US/Bay/SF prices $586,666,667 / $838,095,238 / $2,933,333,333. Net resources $100,074; net US/Bay/SF prices $533,727,393 / $762,467,704 / $2,668,636,964. Prices per DALY; signed net-resource diagnostics retained.
no_quantified_allocation: SF donor No finite positive-health ratio per DALY. US/Bay/SF QALYs 0 / 0 / 0. Donor US/Bay/SF No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Gross resources $100,000; gross US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Net resources $100,000; net US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Prices per DALY; signed net-resource diagnostics retained.
replacement_only: SF donor No finite positive-health ratio per DALY. US/Bay/SF QALYs 0 / 0 / 0. Donor US/Bay/SF No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Gross resources $125,000; gross US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Net resources $100,000; net US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Prices per DALY; signed net-resource diagnostics retained.
no_timing_advantage: SF donor No finite positive-health ratio per DALY. US/Bay/SF QALYs 0 / 0 / 0. Donor US/Bay/SF No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Gross resources $125,000; gross US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Net resources $100,369; net US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Prices per DALY; signed net-resource diagnostics retained.
shorter_wait_transfer: SF donor $7.1M per DALY. US/Bay/SF QALYs 0.035 / 0.0315 / 0.014. Donor US/Bay/SF $28,571,429 / $31,746,032 / $71,428,571. Gross resources $125,000; gross US/Bay/SF prices $35,714,286 / $39,682,540 / $89,285,714. Net resources $100,093; net US/Bay/SF prices $28,598,114 / $31,775,682 / $71,495,285. Prices per DALY; signed net-resource diagnostics retained.
no_credit_future_resource_offset: SF donor $1.8M per DALY. US/Bay/SF QALYs 0.14 / 0.126 / 0.056. Donor US/Bay/SF $7,142,857 / $7,936,508 / $17,857,143. Gross resources $125,000; gross US/Bay/SF prices $8,928,571 / $9,920,635 / $22,321,429. Net resources $112,500; net US/Bay/SF prices $8,035,714 / $8,928,571 / $20,089,286. Prices per DALY; signed net-resource diagnostics retained.
additional_public_resources: SF donor $1.8M per DALY. US/Bay/SF QALYs 0.14 / 0.126 / 0.056. Donor US/Bay/SF $7,142,857 / $7,936,508 / $17,857,143. Gross resources $130,000; gross US/Bay/SF prices $9,285,714 / $10,317,460 / $23,214,286. Net resources $102,869; net US/Bay/SF prices $7,347,816 / $8,164,241 / $18,369,541. Prices per DALY; signed net-resource diagnostics retained.
donor_pays_clinical_resources: SF donor $6.3M per DALY. US/Bay/SF QALYs 0.04 / 0.036 / 0.016. Donor US/Bay/SF $25,000,000 / $27,777,778 / $62,500,000. Gross resources $100,000; gross US/Bay/SF prices $25,000,000 / $27,777,778 / $62,500,000. Net resources $100,000; net US/Bay/SF prices $25,000,000 / $27,777,778 / $62,500,000. Prices per DALY; signed net-resource diagnostics retained.
shared_extra_harm: SF donor No finite positive-health ratio per DALY. US/Bay/SF QALYs -0.06 / -0.054 / -0.024. Donor US/Bay/SF No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Gross resources $125,000; gross US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Net resources $100,369; net US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Prices per DALY; signed net-resource diagnostics retained.
independent_harm_no_activity: SF donor No finite positive-health ratio per DALY. US/Bay/SF QALYs -0.2 / -0.18 / -0.08. Donor US/Bay/SF No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Gross resources $100,000; gross US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Net resources $100,000; net US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Prices per DALY; signed net-resource diagnostics retained.
target_failure_displaces_alternative: SF donor No finite positive-health ratio per DALY. US/Bay/SF QALYs -1 / -0.9 / -0.4. Donor US/Bay/SF No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Gross resources $125,000; gross US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Net resources $100,369; net US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Prices per DALY; signed net-resource diagnostics retained.
no_sf_health: SF donor No finite positive-health ratio per DALY. US/Bay/SF QALYs 0.14 / 0.126 / 0. Donor US/Bay/SF $7,142,857 / $7,936,508 / No finite positive-health ratio. Gross resources $125,000; gross US/Bay/SF prices $8,928,571 / $9,920,635 / No finite positive-health ratio. Net resources $100,369; net US/Bay/SF prices $7,169,245 / $7,965,828 / No finite positive-health ratio. Prices per DALY; signed net-resource diagnostics retained.
negative_clinical_transfer: SF donor No finite positive-health ratio per DALY. US/Bay/SF QALYs -0.14 / -0.126 / -0.056. Donor US/Bay/SF No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Gross resources $125,000; gross US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Net resources $100,369; net US/Bay/SF prices No finite positive-health ratio / No finite positive-health ratio / No finite positive-health ratio. Prices per DALY; signed net-resource diagnostics retained.
low_cash_unverified: SF donor $446K per DALY. US/Bay/SF QALYs 0.56 / 0.504 / 0.224. Donor US/Bay/SF $1,785,714 / $1,984,127 / $4,464,286. Gross resources $200,000; gross US/Bay/SF prices $3,571,429 / $3,968,254 / $8,928,571. Net resources $101,478; net US/Bay/SF prices $1,812,102 / $2,013,447 / $4,530,256. Prices per DALY; signed net-resource diagnostics retained.
zero_outside_resource_scenario: SF donor $1.8M per DALY. US/Bay/SF QALYs 0.14 / 0.126 / 0.056. Donor US/Bay/SF $7,142,857 / $7,936,508 / $17,857,143. Gross resources $100,000; gross US/Bay/SF prices $7,142,857 / $7,936,508 / $17,857,143. Net resources $100,000; net US/Bay/SF prices $7,142,857 / $7,936,508 / $17,857,143. Prices per DALY; signed net-resource diagnostics retained.
net_saving_diagnostic: SF donor $1.8M per DALY. US/Bay/SF QALYs 0.14 / 0.126 / 0.056. Donor US/Bay/SF $7,142,857 / $7,936,508 / $17,857,143. Gross resources $125,000; gross US/Bay/SF prices $8,928,571 / $9,920,635 / $22,321,429. Net resources $-49,631; net US/Bay/SF prices $-3,545,041 / $-3,938,934 / $-8,862,602. Prices per DALY; signed net-resource diagnostics retained.

Historical and current scenarios are not confidence bounds or verified donation offers.

5. Funding and previous grants

Confirm fully loaded course costs, patient alternatives and additional capacity before relying on this conditional estimate.

Original selected FY2022–24 Form 990 fields show average functional expenses of $2.5M. Revenue-netted rental expenses raise arithmetic gross expenses to $6.4M, but neither figure identifies cash flow, consolidated economic cost or additional surgery capacity. The internal charity-care transfer must not be counted again as external resources.

This review does not establish a verified marginal funding offer or a complete history of grants.

Donate

Opens the organization’s giving page. A general donation may not fund the specific activity modeled here; confirm allocation with the recipient.

6. Sources

What we do. Pacific Vision Foundation. Primary funding body, shared clinical pathway and wider mission.. Published: Undated current page; retrieved: September 8, 2026.
2025 impact report. Pacific Vision Foundation. Primary2025 activities/text; screenshot failed so chart shares/revenue not used. Annual surgery versus cumulative charity counts distinguished.. Published: Announced June 11, 2026; July 2026 PDF path; retrieved: September 8, 2026.
FY2024 Form990. Pacific Vision Foundation; IRS filing hosted by ProPublica. Primary e-file return read; rental expenses netted outside functional expenses. Not an obtained consolidated audit.. Published: November 17, 2025 filing; retrieved: September 8, 2026.
Cost effectiveness of expedited cataract surgery. First-eye trial economic investigators; British Journal of Ophthalmology. Primary extraction retained from accepted legacy audit; direct current NIH access challenge. Missing18/306 and assumed one-year utility shape retained.. Published: 2007; retrieved: September 8, 2026.
Ways to give. Pacific Vision Foundation. Ordinary recipient; no independently verified cataract-restricted open tranche.. Published: Undated official giving route; retrieved: September 8, 2026.
Selected main-body impact/appeal text. Pacific Vision Foundation. Selected main-body impact/appeal text. Published: Source period described in report; retrieved: 2026-10-03.
Selected giving/sponsor paragraphs. Pacific Vision Foundation. Selected giving/sponsor paragraphs. Published: Source period described in report; retrieved: 2026-10-03.
Provider/Lions uninsured-low-income route paragraphs. Pacific Vision Foundation. Provider/Lions uninsured-low-income route paragraphs. Published: Source period described in report; retrieved: 2026-10-03.
OriginalFY2022 identity,PartIexpense/PartIXtotal/PartVIIIrental selected text; not entire return. IRS original return. OriginalFY2022 identity,PartIexpense/PartIXtotal/PartVIIIrental selected text; not entire return. Published: Source period described in report; retrieved: 2026-10-03.
OriginalFY2023 same selected fields. IRS original return. OriginalFY2023 same selected fields. Published: Source period described in report; retrieved: 2026-10-03.
OriginalFY2024 identity,PartI/IXexpenses,VIIIrental,charitycare selected fields. IRS original return. OriginalFY2024 identity,PartI/IXexpenses,VIIIrental,charitycare selected fields. Published: Source period described in report; retrieved: 2026-10-03.
Selected relatedentity/control/transfer/transactionRnote only. IRS original return. Selected relatedentity/control/transfer/transactionRnote only. Published: Source period described in report; retrieved: 2026-10-03.
Selected primary indexed abstract design/results; not fullpaper. Indexed original trial abstract. Selected primary indexed abstract design/results; not fullpaper. Published: Source period described in report; retrieved: 2026-10-03.
Health and income welfare comparison. Coefficient Giving. Welfare crosswalk; not local causal evidence. Published: Framework; retrieved: Previously reviewed framework.

Annual expenses: years and sources

Average annual expenses (three consecutive fiscal years): $2,480,683. Organization size is separate from the modeled cost-effectiveness of a donation.

Pacific Vision Foundation

Form 990 reported whole-entity expenses; includes program, administration and fundraising costs, but excludes costs netted against revenue.

Calendar years ended December 31. Latest listed original return is 2024. Filing-entity expenses; rental expenses netted outside Form 990 functional expenses are excluded. Not a consolidated total of related entities.